What FDA and Regulatory Changes Could Mean For Peptide Clinics

The regulatory conversation around peptides has shifted quickly over the last two years, and longevity clinics are sitting in the middle of it. FDA scrutiny of compounded GLP-1s, the 503A bulks list reviews, and a growing focus on telehealth prescribing have all converged at the same time. For clinic operators, the question is no longer whether the rules will change. It is how to keep delivering care when they do.

At Corepay, we are at the forefront of compliance and have been monitoring this subject very closely as things progress. Let’s break down where regulation is heading, which peptides are most exposed, and why the clinics that adapt their operations early are positioned best for what comes next.

• More on peptide merchant accounts
• Related: GLP-1 payment compliance for medspas

This Is Not the Same Conversation as Research Peptides (RUO)

Most of the public debate about peptides centers on Research Use Only products, the vials sold online with a “not for human consumption” label.

That is a real conversation, but it is a different conversation than the one happening inside licensed clinics. Conflating the two leads to bad policy assumptions and worse operational decisions.

Research Use Only, or RUO, is a labeling category for materials sold for laboratory study, not clinical use. RUO sellers operate as chemical suppliers. They do not see patients, write prescriptions, or take responsibility for outcomes. The legal and ethical posture is built around the disclaimer on the label.

Clinical peptide therapy is a healthcare service. A licensed provider evaluates a patient, prescribes a protocol, sources the medication through a compounding pharmacy or FDA-approved channel, and stays involved in follow-up. The product is one input in a longer process that includes labs, dosing adjustments, and ongoing monitoring.

The operational difference matters most in the recurring patient relationship. A research seller closes a transaction and moves on. A clinic books the next visit, refills the protocol, runs follow-up labs, and bills monthly or quarterly. That relationship is what regulators, acquiring banks, and card networks evaluate when they look at a clinic, and it is what most generic payment platforms are not built to support.

Treating the two business models as the same category creates risk in both directions. Clinics get judged by the assumptions of a chemical supply business, and the conversation about clinical access gets confused with the conversation about gray-market sales.

	Research Peptide Sellers (RUO)	Licensed Peptide Clinics
Buyer	Anonymous online purchaser	Evaluated patient with a medical record
Provider Involvement	None after sale	Prescribing, monitoring, adjustments
Product Source	Chemical suppliers, often imported	503A or 503B compounding pharmacies, FDA-approved products
Revenue Model	One-off transactions	Memberships, recurring protocols, longitudinal care
Regulatory Posture	RUO labeling disclaimer	State medical board, DEA, FDA, payer compliance
Payment Profile	Ecommerce checkout	Recurring patient billing, clinical documentation, healthcare workflows

Which Peptides Are Longevity Clinics Watching Most Closely?

Several peptides have moved to the center of regulatory attention, and the list keeps shifting. Clinic operators are watching a handful of categories more carefully than others.

Compounded GLP-1s (Semaglutide and Tirzepatide)

The FDA ended its enforcement discretion on compounded semaglutide and tirzepatide in May 2025 once the official shortage list was resolved. Clinics that built weight management and metabolic programs around compounded GLP-1s have had to rebuild around FDA-approved supply, and the payment side of those programs has been under heavy review.

BPC-157, Ipamorelin, CJC-1295, and Other 503A Candidates

Several growth-hormone-releasing and recovery-focused peptides have been evaluated for inclusion on the FDA’s 503A bulk drug substances list. The bulks list determines which substances licensed compounding pharmacies can use to prepare patient-specific medications.

Peptides that fail to make the list become difficult to source through compliant channels, and clinics that built protocols around them face a sourcing problem, not just a paperwork problem.

Thymosin Alpha-1, Sermorelin, and Immune or Endocrine Peptides

This is the group most clinic operators say they want clarity on. Some have an existing FDA-approved use, some are widely compounded, and the regulatory pathway varies by indication. The watch here is less about a single ruling and more about how broadly future decisions get applied across the category.

Retatrutide

Retatrutide has become one of the most watched compounds across longevity, wellness, and medical weight management because of growing interest around metabolic health and long-term care models. Unlike many compounds discussed in longevity circles, retatrutide follows a more traditional pharmaceutical pathway rather than the research peptide market. For clinics, the bigger opportunity is not predicting availability. It is preparing for how future treatment models could increase demand for recurring care, memberships, patient continuity, and healthcare infrastructure designed for long-term patient relationships.

Novel and Investigational Peptides

Newer entries that have not gone through a formal review create the most uncertainty. Clinics offering them are often relying on the compounding pathway by default, which means a single regulatory decision can change accessibility overnight.

If Accessibility Changes, Clinics May Start Looking More Like Subscription Healthcare Businesses

When a peptide moves out of easy compounding access, the clinic does not stop caring for the patient. It substitutes a different protocol, adjusts the program, and continues the relationship. That is the practical reason longevity clinics are starting to operate more like ongoing healthcare businesses than retail wellness shops.

The shift shows up in a few specific places. Memberships replace one-off injections. Quarterly programs include labs, provider visits, and protocol adjustments alongside the medication. Billing moves from a single charge to recurring patient billing, often with clinical documentation attached to each renewal. Care becomes longitudinal, and the payment infrastructure has to keep up with the care model.

The clinics making this shift on purpose tend to do better when the regulatory landscape moves. Their revenue is tied to the patient relationship, not to any single peptide. A protocol change is a clinical decision, not a business model crisis.

Why Generic Payment Platforms May Struggle With the Next Phase of Longevity Clinics

Most payment aggregators were built for a different business: a single checkout, a single product, a single transaction. They work well for facials, retail wellness, and consumer ecommerce. They struggle when the business looks like healthcare.

A few specific gaps come up again and again with longevity clinics:

• Underwriting assumes retail, not clinical care. The merchant file describes the business as an ecommerce wellness brand, even though the actual operation is provider-led care with prescriptions, labs, and recurring patient billing. When the platform reviews the account later, the mismatch becomes the problem.
• Recurring patient billing is treated as ecommerce subscriptions. Membership and protocol renewals run through the same rails as a monthly box subscription, with no support for clinical documentation, prior authorization, or chargeback context tied to medical care.
• One-size-fits-all risk reviews. A spike in volume, a higher-than-average ticket, or a single chargeback triggers a generic review process, often resulting in account holds or termination instead of a substantive conversation about the underlying clinical workflow.
• No supporting infrastructure for the regulatory layer. LegitScript certification, FDA-approved sourcing verification, state licensure review, and card network compliance are out of scope for most aggregators. The clinic ends up assembling that layer on its own, with no help from the payment provider.

None of this is a failure of the aggregator model. It is a category mismatch. Retail payment platforms were not designed to underwrite healthcare delivery, and the next phase of longevity clinics is healthcare delivery.

The Clinics That Win Will Be The Ones That Prepare Operationally First

The clinics that handle a regulatory shift well usually share one trait. They aligned their underwriting, their billing, and their payment infrastructure with how care is actually delivered, before they had to. That alignment is what gives them room to maneuver when a peptide moves off the bulks list, a compounding pathway closes, or a new compliance requirement lands.

A recent example: a growing longevity clinic launched on an aggregator because onboarding was fast and payments worked well in the early stages. As the business introduced memberships, recurring treatment plans, and newer wellness programs, the payment environment became harder to operate inside. Reviews became more frequent. Billing workflows became more complex. Leadership realized the account structure and underwriting assumptions no longer reflected how care was actually being delivered.

At Corepay, we helped the clinic transition to a compliance-first approach built around healthcare operations rather than retail ecommerce. That meant aligning underwriting with the clinic’s business model, supporting recurring patient billing, and building infrastructure designed for long-term continuity instead of short-term payment acceptance.

The payment side is not the whole story, and we would not pretend otherwise. Regulatory direction, clinical protocols, and sourcing decisions are bigger questions than how a charge gets processed. What the payment infrastructure does is buy the clinic time and stability to make those bigger decisions on its own schedule, instead of reacting to an account review at the worst possible moment.

If you operate a peptide or longevity clinic and the gap between your business model and your payment setup has been showing, we would like to hear about it. Talk to our team about peptide merchant accounts built for clinical operations, recurring patient billing, and the regulatory environment longevity clinics are actually working in.

*Important Note*

This article is intended for informational and industry discussion purposes only and should not be interpreted as medical, legal, regulatory, or investment advice. References to peptides, longevity clinics, and future regulatory developments do not imply approval, availability, efficacy, or endorsement of any specific therapy or treatment model. Regulatory status may change over time and healthcare businesses should work with qualified legal, compliance, medical, and pharmacy professionals when evaluating new treatment offerings. Corepay supports compliant healthcare businesses and does not support research-use-only (RUO) peptide sales.